First non-hormonal remedy approved for menopausal hot flashes

(HealthDay)—Brisdelle (paroxetine) has been approved by the U.S. Food and Drug Administration as the first non-hormonal treatment to treat hot flashes associated with menopause.

All prior FDA-approved drugs for hot flashes contain either the alone or the hormonal combination of estrogen and progestin, the agency said in a news release.

Brisdelle's active ingredient is paroxetine, in a smaller amount than the same active ingredient in the antidepressant Paxil. It's not understood how paroxetine treats hot flashes, the FDA said.

Hot flashes affect up to 75 percent of all women, and can linger for as long as five years. Brisdelle's safety and effectiveness in treating the condition were evaluated in clinical studies involving 1,175 post-menopausal women with moderate-to-severe hot flashes. The most common side effects of the once-daily drug were headache, fatigue and nausea/vomiting.

Paroxetine, a (SSRI), has the same boxed label warning as other in its class. The label warns of possible increased risk of suicide among children and young adults.

Brisdelle's label also warns of a possible reduction in the effectiveness of tamoxifen—a drug prescribed to treat breast cancer—if both medications are taken together. Other potential serious side effects include increased risk of bleeding and developing a condition called serotonin syndrome, the FDA said.

Brisdelle is marketed by Noven Therapeutics, based in Miami, Fla.


Explore further

Hot flashes can come back after SSRI

More information: To learn more about this approval, visit the FDA.

Health News Copyright © 2013 HealthDay. All rights reserved.

Citation: First non-hormonal remedy approved for menopausal hot flashes (2013, July 1) retrieved 21 October 2019 from https://medicalxpress.com/news/2013-07-non-hormonal-remedy-menopausal-hot.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more